Heart Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Disease
Studies from A. Wakil and colleagues reveal new findings on heart disease
December 28th, 2008
"Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease," investigators in the United Kingdom report. "A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database. The mean cumulative dose of...
Source: Heart Disease Weekly (2008-12-28)
|
